Status:

COMPLETED

Effects of Divalproex Sodium on Food Intake, Energy Expenditure, and Posture Allocation

Lead Sponsor:

Pennington Biomedical Research Center

Collaborating Sponsors:

Abbott

Conditions:

Healthy

Eligibility:

All Genders

18-54 years

Phase:

PHASE4

Brief Summary

The purpose of the proposed study is to identify the mechanisms responsible for the weight gain associated with Depakote treatment, and to identify methods to prevent and treat weight gain in people t...

Detailed Description

Depakote (Abbott Laboratories, Abbott Park, IL) is an anti-convulsant medication used to treat epilepsy \[1\] and mania associated with bipolar disorder \[2, 3\]. Depakote also is used as a prophylaxi...

Eligibility Criteria

Inclusion

  • Healthy male or female, age 18 to 54 years
  • 20 \< Body Mass Index (BMI, kg/m2) \< 30
  • Willing to have a blood sample stored for possible future genetic testing

Exclusion

  • For females, pregnant or unwilling to use an effective form of contraception while on this study (hormonal methods like birth control pills, implants or shots; barrier methods like condoms or diaphragms with foam; surgical sterilization; or abstinence)
  • For females, use of any other oral contraceptive other than monophasic oral contraceptives
  • For females, irregular menstrual cycles
  • For females, history of partial hysterectomy
  • For females, nursing
  • For females, history of polycystic ovarian syndrome
  • Aspirin use or the refusal to abstain from aspirin use during the study
  • Current or history of urea cycle disorders
  • Tobacco users
  • Use of anti-convulsant medication
  • Use of barbiturates, such as Phenobarbital
  • Use of tranquilizers, such as Xanax and Valium
  • Use of blood thinners, such as Coumadin
  • Use of anti-depressant medication
  • Liver disease or impaired liver function
  • History of pancreatitis
  • Regular (4 or more days per week) consumption of 3 or more alcoholic beverages a day
  • Refusal to abstain from alcohol intake during the study
  • Dietary restraint score \> 14 or disinhibition score \> 12 on the Eating Inventory \[19\]
  • Dislike or allergy to the food used during the food intake tests
  • Unwilling to wear an IDEEA™ during the study
  • Unwilling to wear an accelerometer during the study

Key Trial Info

Start Date :

February 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2006

Estimated Enrollment :

57 Patients enrolled

Trial Details

Trial ID

NCT00287053

Start Date

February 1 2006

End Date

October 1 2006

Last Update

February 8 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Pennington Biomedical Research Center

Baton Rouge, Louisiana, United States, 70808